drugset / Trial / NCT02138331

Effect of Microvesicles and Exosomes Therapy on β-cell Mass in Type I Diabetes Mellitus (T1DM)

NCT02138331 ↗

NaSingle-groupOpen-labelTreatment

Summary

Type 1 diabetes mellitus is strictly autoimmune mediated disease destructing the islets β-cell of the pancreas. Mesenchymal stem cells and its microvesicles are reported as an anti-inflammatory agents. We hypothesis that intravenous infusion of cell free umbilical cord-blood derived MSC microvesicles may reduce the inflammatory state and hence improve the β-cell mass as well as the glycemic control of the patients of T1DM.

Timeline

Start
2014-04
Primary completion
2014-07
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject MSC exosomes Other / unclassified 1.22e+06 cells/kg Intravenous